REVIEW PAPER
Updated principles of prevention, diagnosis and treatment of COVID-19 in children in Poland – recommendations for paediatricians and family medicine doctors
1
Department of Children’s Infectious Diseases, Medical University of Warsaw, Poland
2
Regional Hospital for Infectious Diseases, Warsaw, Poland
3
Department of Infectious Diseases and Paediatric Neurology, Poznan University of Medical Sciences, Poznan, Poland
4
Department of Paediatrics, Paediatric Nephrology and Allergology, Military Institute of Medicine, Central Clinical Hospital of the Ministry of Defence (MON), Warsaw, Poland
5
Department of Paediatrics with Medical Assessment Unit, Medical University of Warsaw, Warsaw, Poland
6
Department of Paediatric Infectious Diseases, Medical University of Lodz, Lodz, Poland
7
Department of Infectious Diseases and Hepatology, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University, Torun, Poland
8
Department of Paediatric Infectious Diseases, Medical University of Bialystok, Bialystok, Poland
9
2nd Department of Paediatrics, Centre of Postgraduate Medical Education, Warsaw, Poland
10
Department of Paediatric and Neonatal Diseases of the Central Clinical Hospital of the Ministry of the Interior and Administration, Warsaw, Poland
11
Department of Paediatrics and Infectious Diseases, Wroclaw Medical University, Wroclaw, Poland
12
Department of Preventive Medicine, Poznan University of Medical Sciences, Poznan, Poland
13
Department of Infectious Diseases, Specialized Health Care Center for Women and Children, Poznan, Poland
14
Department of Pediatrics, Pediatric Oncology and Immunology, Pomeranian Medical University, Szczecin, Poland
15
Department of Paediatrics, Centre of Postgraduate Medical Education, Warsaw, Poland
16
National Consultant in the Field of Paediatrics, Warsaw, Poland
Submission date: 2022-03-30
Final revision date: 2022-04-26
Acceptance date: 2022-04-26
Publication date: 2022-06-08
Pediatr Pol 2022;97(2):71-80
KEYWORDS
TOPICS
ABSTRACT
Since late 2021, we have observed a significant increase in the proportion of children infected with SARS-CoV-2. The course of the disease in children is usually sparsely symptomatic or asymptomatic. However, the predominance of new virus variants makes children more likely to become symptomatically ill and require hospitalisation. This paper aims to update recommendations for managing a child with COVID-19 in out- and inpatient settings. Current options for prevention and antiviral treatment are discussed, noting the limited availability of therapy for children. In most children with COVID-19, the basis for treatment remains symptomatic and supportive therapy and measures to reduce SARS-CoV-2 infection spread.
REFERENCES (30)
1.
Viner R, Mytton O, Bonell C, et al. Susceptibility to SARS-CoV-2 infection among children and adolescents compared with adults: a systematic review and meta-analysis. JAMA Pediatr 2021; 175: 143-156.
2.
Parsons S, Sass L. Children’s Hospital of the King’s Daughters (CHKD) Treatment Guideline for COVID-19 in Children. Available from: https://www.chkd.org/uploadedF... (lastly accessed 20 March 2020).
3.
Flisiak R, Parczewski M, Horban A, et al. Zalecenia diagnostyki i terapii zakażeń SARS-CoV-2 Polskiego Towarzystwa Epidemiologów i Lekarzy Chorób Zakaźnych 12 listopada 2021 roku. Aneks 1 do rekomendacji z 26 kwietnia 2021 roku. Available from: http://www.pteilchz.org.pl/wp-... (lastly accessed 24 January 2022).
4.
Charakterystyka Produktu Leczniczego COMIRNATY. Available from: https://www.ema.europa.eu/en/d....
6.
Charakterystyka Produktu Leczniczego SPIKEVAX. Available from: https://www.ema.europa.eu/en/d....
7.
Kwestionariusz wstępnego wywiadu przesiewowego przed szczepieniem dziecka w wieku 5–11 lat przeciw COVID-19. Available from: https://pacjent.gov.pl/sites/d....
8.
Charakterystyka Produktu Leczniczego Ronapreve. Available from: https://www.ema.europa.eu/en/d....
11.
Drain PK. Rapid diagnostic testing for SARS-CoV-2. N Engl J Med 2022; 386: 264-272.
12.
Kim L, Whitaker M, O’Halloran A, et al. Hospitalization rates and characteristics of children aged < 18 years hospitalized with laboratory-confirmed COVID-19 – COVID-NET, 14 States, March 1 – 25 July 2020. MMWR Morb Mortal Wkly Rep 2020; 69: 1081-1088.
13.
Hoang A, Chorath K, Moreira A, et al. COVID-19 in 7780 pediatric patients: a systematic review. EClinicalMedicine 2020; 24: 100433.
14.
Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter initial guidance on use of antivirals for children with COVID-19/SARS-CoV-2. J Pediatric Infect Dis Soc 2020; 9: 701-715.
15.
Chiotos K, Hayes M, Kimberlin DW, et al. Multicenter interim guidance on use of antivirals for children with coronavirus disease 2019/severe acute respiratory syndrome coronavirus 2. J Pediatric Infect Dis Soc 2021; 10: 34-48.
16.
Koletsi P, Antoniadi M, Mermiri D, et al. A toddler diagnosed with severe postinfectious bronchiolitis obliterans and COVID-19 infection. Pediatr Pulmonol 2021; 56: 2381-2384.
17.
Andre N, Rouger-Gaudichon J, Brethon B, et al. COVID-19 in pediatric oncology from French pediatric oncology and hematology centers: high risk of severe forms? Pediatr Blood Cancer 2020; 67: e28392.
18.
Paxlovid – Summary of Product Characteristics. Available from: https://www.gov.uk/government/....
19.
Paret M, Lighter J, Pellett Madan R, et al. SARS-CoV-2 infection (COVID-19) in febrile infants without respiratory distress. Clin Infect Dis 2020; 71: 2243-2245.
21.
FDA Emergency Use Authorization (EUA) for the treatment of COVID-19 in hospitalised pediatric patients weighing 3.5 kg to < 40 kg or < 12 lat and ≥3.5 kg. Available from: https://www.fda.gov/media/1375....
22.
US Food and Drug Administration. FDA News Release. COVID-19 Update: FDA broadens emergency use authorisation for Veklury (remdesivir) to include all hospitalised patients for treatment of COVID-19. Available from: https://www.fda.gov/news-event... (lastly accessed 1 September 2020).
23.
Ranjbar K, Moghadami M, Mirahmadizadeh A, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalised COVID-19 patients: a triple-blinded randomised controlled trial. BMC Infect Dis 2021; 21: 337-344.
24.
Food and Drug Administration. Letter of authorisation: EUA for baricitinib (Olumiant), in combination with remdesivir (Veklury), for the treatment of suspected or laboratory confirmed coronavirus disease 2019 (COVID-19). Available from: https://www.fda.gov/media/1438....
25.
FDA broadens existing emergency use of Lilly and Incyte’s baricitinib in patients hospitalised with COVID-19 requiring oxygen. Availably from: https://investor.lilly.com/new....
26.
Charakterystyka Produktu Leczniczego RoActemra. Available from: https://www.roche.pl/content/d....
27.
Tocilizumab (Actemra) [package insert]. Food and Drug Administration. 2019. Available from: https://www.accessdata.fda.gov....
28.
Liverpool Drug Interaction Group. Detailed recommendations for interactions with experimental COVID-19 therapies. Available from: http://www.covid19-druginterac... (lastly accessed 31 January 2022).
29.
Liverpool Drug Interaction Group. Administration in cases of swallowing difficulties. Available from: http://www.covid19-druginterac... Updated 01/17/2022 (lastly accessed 31 January 2022).
30.
Deklaracja Helsińska Światowego Stowarzyszenia Lekarzy (WMA1). Etyczne zasady prowadzenia badań medycznych z udziałem ludzi. Przyjęta przez 18. Zgromadzenie Ogólne Światowego Stowarzyszenia Lekarzy (WMA), Helsinki, Finlandia, czerwiec 1964 r., z późniejszymi zmianami.
Share
RELATED ARTICLE
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
